Key facts
- Notable investors include Remiges Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Endurance Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Endurance Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Endurance Bio
Developer of small molecule therapeutics designed to improve cellular function and treat metabolic and neurodegenerative diseases. The company offers orally bioavailable compounds, mitochondrial and lysosomal pathway activation, and regulation of cellular metabolism, enabling biopharmaceutical organizations to target disease mechanisms and support therapeutic development.
- Sector
- Healthcare
- HQ
- Cupertino, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- endurance-bio.com/
- Ownership
- Privately Held (backing)
Endurance Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Endurance Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Endurance Bio in its N-PORT filings yet. We sweep new filings monthly.